Nyxoah (NASDAQ:NYXH) Stock Price Target Lowered at Cantor Fitzgerald

Posted by on Oct 27th, 2026

Nyxoah (NASDAQ:NYXH – Get Free Report) had its price target lowered by equities research analysts at Cantor Fitzgerald to $3.00 in a research note issued on Tuesday, MarketBeat Ratings reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price objective would suggest a potential upside of 229.38% from the company’s previous close.

Several other brokerages also recently weighed in on NYXH. Wall Street Zen downgraded shares of Nyxoah from a “hold” rating to a “sell” rating in a research note on Sunday, August 9th. Piper Sandler reaffirmed an “overweight” rating and set a $6.00 target price (down from $7.00) on shares of Nyxoah in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nyxoah in a research note on Wednesday, August 19th. Robert W. Baird set a $2.31 target price on shares of Nyxoah in a research note on Thursday, August 6th. Finally, Oppenheimer set a $4.00 target price on shares of Nyxoah in a research note on Thursday, August 6th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $3.55.

View Our Latest Analysis on NYXH

Nyxoah Stock Up 6.4%

NYXH traded up $0.05 during trading hours on Tuesday, hitting $0.91. 295,870 shares of the company’s stock were exchanged, compared to its average volume of 206,015. Nyxoah has a 12-month low of $0.80 and a 12-month high of $5.92. The firm has a 50 day moving average of $1.40 and a 200 day moving average of $2.60. The firm has a market cap of $35.30 million, a P/E ratio of -0.36 and a beta of 1.65. The company has a current ratio of 2.38, a quick ratio of 2.31 and a debt-to-equity ratio of 0.44.

Nyxoah (NASDAQ:NYXH – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.20). Nyxoah had a negative return on equity of 178.90% and a negative net margin of 443.16%. The business had revenue of $8.76 million for the quarter, compared to analysts’ expectations of $8.64 million. Analysts predict that Nyxoah will post -1.44 EPS for the current fiscal year.

Institutional Investors Weigh In On Nyxoah

A number of large investors have recently modified their holdings of the company. Readystate Asset Management LP purchased a new stake in shares of Nyxoah in the 2nd quarter valued at approximately $351,000. IFP Advisors Inc increased its position in shares of Nyxoah by 35.6% in the 2nd quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock valued at $200,000 after purchasing an additional 31,061 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Nyxoah in the 2nd quarter valued at approximately $169,000.

About Nyxoah

(Get Free Report)

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.

Read More

Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.